Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The new patents cover critical advancements in cochlear implant technology
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
This transaction fundamentally strengthens Scinai's CDMO platform
Subscribe To Our Newsletter & Stay Updated
